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ABSTRACT 
This study assessed agreement between two measures 
of medicine use, self-report by mail and pharmaceu- 
tical claims data, for a national sample (N = 4687) of 
older women aged 79 to 84 in 2005, from the Austra- 
lian Longitudinal Study on Women’s Health. Medi- 
cines used for common chronic diseases in older peo- 
ple were selected, with pharmaceutical claims data 
retrieval periods of three and six months. For six 
month retrieval, Kappa’s ranged between 0.44 (ner- 
vous system medicines) and 0.94 (glucose lowering 
medicines). For three month retrieval, aspirin (Kappa: 
0.35) and folic acid (Kappa = 0.48) had lowest agree- 
ment. Women were least able to accurately report use 
of nervous system medicines (sensitivity < 50%), and 
most accurately report glucose lowering medicines 
use (sensitivity > 80%). Specificity was consistently 
high across all classes, suggesting women could accu- 
rately report using a medicine. Pharmaceutical claims 
data can assist evaluation of judicious medicines use, 
changes to availability and uptake of medicines, and 
track medicine expenditure for chronic conditions. 
Over-the-counter medicines, medicines not covered by 
pharmaceutical subsidies and those used on an as 
needed basis may be best measured by self-report, as 
use may be underestimated using pharmaceutical 
claims data. 
 
Keywords: Medicines; Ageing; Agreement; Women; 
Self-Report; Pharmacy Records; Validation; Survey 
1. INTRODUCTION 
Linking routinely collected administrative data on health 
and health service use to self-report data from surveys 
can enhance the breadth and efficiency of population 
health research. Record linkage also provides a mecha- 
nism to assess the accuracy and consistency of each data 
source. Researchers and clinicians need to be aware of 
the strengths and limitations of using various sources of 
data for decision-making. Pharmaceutical claims data 
can be used to evaluate the appropriate use of medicines, 
and the impact of changes to the availability and uptake 
of medicines. These data can also be used to track medi- 
cines expenditure, particularly for chronic conditions. 
Hence it is important to know how closely pharmaceuti- 
cal claims data compare to self-reported medication use 
and whether the discrepancies between the two sources 
are more pronounced for some types of medications. 
The benefits and limitations of collecting and analys- 
ing self-reported medicines use have been addressed in 
previous research [1]. For example, self-report can be 
used to measure use of over-the-counter medicines and to 
assess compliance behaviours such as adherence to tim- 
ing directions, which are often not measured in pharma- 
ceutical claims databases. However, the quality of survey 
data on self-reported medicines use depends on the ac- 
curacy of recall of participants. Inaccurate recall of me- 
dicines use can lead to misclassified medicines exposure 
and incorrect risk and prevalence estimates of medicines 
use in case control studies [2,3], randomised controlled 
trials and population and longitudinal studies. Accuracy 
and recall in the self-report of medicines use depend on a 
number of research design, medicines related and par- 
ticipant factors. Research design factors include question 
structure [4], interviewer skills and length of recall pe- 
riod. Important medicines related factors impacting on 
medicines recall are, for example, class of medicines [1], 
regularity and frequency of use [1,5] or seriousness of 
conditions for which used [5]. Recall can also depend on 
participant characteristics, such as income [6] and living 
alone [3,6] but generally gender has no impact [3,7-9]. 
The impact of participant characteristics on medicines 
recall generally varies according to the medicines class *Corresponding author. 
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under investigation [3]. There have been mixed results 
on the impact of age on medicines recall with some stu- 
dies reporting statistically significant associations [6] but 
most not [7-10], although participants with age-related 
memory problems tend to over-report medicines use [11]. 
It is important to understand the reliability and accuracy 
of self-reported medicines use amongst older people gi- 
ven they are the largest users of medicines and com- 
monly have multiple medical conditions. Studies in Aus- 
tralia [1], the Netherlands [8,12], and the US [13] have 
concluded that pharmaceutical claims databases can be a 
useful tool to measure medicines exposure for prescrip- 
tion medicines amongst older people. However, study 
samples are generally drawn from very specific popula- 
tions such as local general practice [1], inner city [12] or 
health maintenance organizations [13] which makes it 
difficult to generalise the results to population based stu- 
dies. In this paper, we draw on a national sample of com- 
munity-living older women that is broadly representative 
of the national population of older women [14] in Austra- 
lia to estimate the agreement and accuracy of self-report 
survey medicines data by comparing it with pharmaceu- 
tical claims data as the reference standard. 
2. MATERIALS AND METHODS 
2.1. The Australian Longitudinal Study on 
Women’s Health 
The Australian Longitudinal Study on Women’s Health 
was designed to investigate multiple factors affecting the 
health and well-being of women. In 1996, women born 
in the years 1921-1926 (aged 70 - 75 years) were ran- 
domly selected from the national Medicare database, 
with over-representation of women living in rural and 
remote areas [14]. Medicare includes all Australian citi- 
zens and permanent residents, regardless of age or in- 
come. The women were sent a mail survey. The baseline 
survey, survey 1 (S1) was completed by 12,432 women 
and these women have now been surveyed five times 
over a 13-year period (1996-2008). Data on medicines 
taken by the women were available from two sources: 
self-report of their prescribed medicines and pharmaceu- 
tical claims data for the same year. 
2.2. Coding of Self-Reported Medicines 
This study uses data from Survey 4 which was conducted 
in 2005 (S4 n = 7158) when the women were aged 79 - 
84 years. Parts of the methods and data have been re- 
ported elsewhere [15]. The women were asked: “Please 
write down the names of all your medicines prescribed 
by a doctor. Where possible, copy names from the pack- 
ets, or obtain a list from your regular pharmacist and re- 
turn it with your survey.” Participants recorded their me- 
dicines in open-ended text-format (see  
www.alswh.org.au). Coding occurred in two steps [15]: 
1) Information provided by the women was entered 
into a database containing four fields: medicine name, 
dosage, frequency and any other information. 
2) The medicines data were then coded according to 
two standard medicines classifications. First, each medi- 
cine was assigned a value for the pharmaceutical name. 
This information was derived from the Australian Statis- 
tics on Medicines (ASM) [16]. Second, all medicines were 
classified according to the Anatomical Therapeutic Che- 
mical (ATC) Classification System 2001 [17]. This infor- 
mation was entered into a database as a medicines list. 
To enable analysis, each medicine was coded to an Ana- 
tomical Therapeutic Chemical (ATC) group according to 
the World Health Organisation (WHO) definitions. Each 
new medicine that was entered, was checked against the 
existing list of medicines in the database. If a new medi- 
cine was found, it was cross referenced with the Monthly 
Index of Medical Specialties (MIMS) [18], the Pharma- 
ceutical Benefits Scheme and the World Health Organi- 
sation Anatomical Therapeutic Chemical Classification 
[15]. 
2.3. Coding of Pharmaceutical Claims Data 
In Australia, pharmaceutical claims data are processed 
through Medicare Australia under the Pharmaceutical 
Benefits Scheme (PBS) and the Repatriation PBS (RPBS) 
for Department of Veterans’ Affairs cardholders. Pharma- 
ceutical claims data have some limitations. First, when a 
person reaches a certain monetary threshold (Safety Net 
Threshold), they are allocated a new identifying number 
which applies to families and not individuals [1]. How- 
ever, the majority of older women in the Australian Lon- 
gitudinal Study on Women’s Health are concession card- 
holders (94%) [19] which improves the completeness of 
the dataset. Second, pharmaceutical claims data does not 
cover all medicines, specifically medicines that are pro- 
vided in hospital, bought over-the-counter and comple- 
mentary medicines. Additionally, pharmaceutical claims 
data exclude prescription medicines that are not subsi- 
dized through the scheme. If the cost of a medicine is be- 
low $5.60 for concession cardholders or $32.60 for non- 
concession cardholders, the women pay for the full cost 
of the medicines, and the prescription will therefore not 
be recorded on the pharmaceutical claims database. Hence, 
pharmaceutical claims data provide an appropriate and 
objective, but not perfect, comparison for self-reported 
use of medicines. Medicines listed in the Pharmaceutical 
Benefits Scheme are coded on the basis of the purpose of 
the medicines (such as the patient’s diagnosis or progno- 
sis) rather than its chemical composition. Each pharma- 
ceutical item number for dispensed medicines was also 
coded to an Anatomical Therapeutic Chemical (ATC) 
group according to the World Health Organisation (WHO) 
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definitions [15,17]. 
2.4. Selected Medicines 
For this study, all medicines are covered under the Phar- 
maceutical Benefits Scheme but some medicines use 
may not be recorded for women who have reached the 
Safety Net, or when medicines such as aspirin that are 
also available over-the-counter are purchased without 
prescription. Appendix shows the selected medicines 
groups, generic names and matching ATC codes [15]. 
These medicines were selected because they are used for 
common chronic conditions such as diabetes, hyperten- 
sion, depression and anxiety [20] Ethics approval was 
received from the University of Newcastle Human Re- 
search Ethics Committee. 
2.5. Statistical Analysis 
Agreement was assessed by determining whether self- 
report and pharmaceutical claims data for each woman 
identified medicines in the same ATC class. Kappa coef- 
ficients and their 95% confidence intervals were calcu- 
lated. The sensitivity, specificity and positive and nega- 
tive predictive values of the self-report data were also 
calculated, with claims data as the reference standard. 
Use of these tests in combination with agreement data 
will often enhance the interpretation of data quality. Also, 
since it is important to investigate what effect different 
retrieval periods prior to the survey date have on the ac- 
curacy of self-report as determined by the pharmaceuti- 
cal claims dataset, two cut-points for the time period 
were used to define “medicines used” based on the speci- 
fic Australian situation: three and six months prior to the 
date of the woman completing the survey. Three and six 
months were chosen because repeat prescriptions are us- 
ually intended to last up to six months. Additionally, the 
majority of the selected medicines are taken regularly 
and unlikely to be discontinued without a replacement 
from another medicine in this class. 
3. RESULTS 
A total of 5494 women provided consent for their survey 
data and pharmaceutical claims data to be linked [15].  
When sociodemographic factors were compared be- 
tween women who consented and those who did not, no 
differences were found between consenters and non- 
consenters in relation to self-rated health, diabetes, Body 
Mass Index, and number of general practitioner visits. 
Consenters were better educated and were more likely to 
be able to manage on their available income (P < 0.0001). 
There were also small but significant differences between 
consenters and non-consenters by area of residence (P < 
0.0001). Compared to non-consenters, a higher propor- 
tion of consenters lived in regional areas and a lower per- 
centage of consenters lived in outer regional and remote 
areas [15]. Of the 7158 women that returned the Survey, 
6,495 (90.7%) completed the self-report medicine ques- 
tion [15]. Of these 6495 women, 4687 (66%) consented 
to the release of their pharmaceutical claims data. Of 
these women, 392 women (8%) did not record any medi- 
cines [15]. The pharmaceutical claims data showed that 
338 (7%) women did not claim any medicines during a 
three months data retrieval period; and 233 (5%) of wo- 
men did not use any medicines during a six months pe- 
riod (Table 1(a)). The longer the retrieval period the 
more likely it was that the women claimed a medicine 
subsidy from the PBS. 
Table 1(b) shows the agreement between self-report 
and pharmaceutical claims data in terms of whether wo- 
men use any medicines or not. Women both under and 
over-report medicines use when compared to pharmaceu- 
tical claims data. For example, under-reporting occurred 
for 240 women who reported that they did not use any 
medicines but pharmaceutical claims data (three months) 
revealed that they had prescriptions filled. Conversely, 
 
Table 1. Self-reported medicines data compared to pharma- 
ceutical claims data with three and six months retrieval pe- 
riods (n = 4687) [15]. 
(a) 
Consenters  Consenters 
 Self-report Claims data  (3 months) 
Claims data 
(6 months)
No medicines 392 (8%) 338 (7%) 233 (5%) 
Recorded medicines 4295 (92%) 4349 (93%) 4454 (95%)
(b) 
Agreement Report of any medicine use 
 Claims data (3 months) Claims data (6 months)
Self-report Yes No Total Yes No Total
Yes 4109 (87.7%) 186 4295 
4191 
(89.4%) 104 4295
No 240 152 (3.2%) 392 263 
129 
(2.8%) 392
Total 4349 338 4687 4454 233 4687
(c) 
Summary statistics Number of medicines 
 Returned surveys in 2005* 
Claims data  
(3 months) 
Claims data  
(6 months) 
Number of 
observations 4687 4687 4687 
Mean 4 5 7 
Median 4 5 6 
Min 0 0 0 
Max 25 23 32 
*Sample excluded women that failed to return their survey in 2005. 
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over-reporting occurred for 186 women who reported 
that they were using a medicine at the time of the survey 
but none could be found in the pharmaceutical claims 
dataset at three months. However, this number declined 
to 104 when using a six month retrieval period. A total of 
152 women (3.2%) had no medicine documented in ei- 
ther the survey data or the pharmaceutical claims data 
(three months) and 129 (2.8%) had no medicine docu- 
mented in either the survey data or pharmaceutical claims 
data (six months). The pharmaceutical claims data showed 
a higher mean and median number of medicines used 
compared to self-report data. 
Table 2 displays the agreement and accuracy of self- 
report compared to pharmaceutical claims data. The pre- 
valence of medicines use is higher in the pharmaceutical 
claims data for the six month retrieval period than self- 
report data, except for aspirin [15]. The prevalence of 
medicines use in the pharmaceutical claims data for three 
month retrieval periods is also generally higher in phar- 
maceutical claims data, except for insulin, thiazide, aspi- 
rin and folic acid. In particular, aspirin use is twice as 
high in self-reported data than in pharmaceutical claims 
 
Table 2. Prevalence of self-report (SR) and pharmaceutical claims data (PBS), kappa (K), sensitivity, specificity and positive and 
negative predictive values of self-report compared to pharmaceutical claims data for older women (N = 4687), 2005 [15]. 
Medicine class-retrieval period Prevalence Kappa Sensitivity Specificity Positive predictive value 
Negative 
predictive value
 SR % PBS % K *95% CI % *95% CI % *95% CI % % 
Drugs that must be taken  
regularly and cannot be bought 
over-the-counter: 
          
Glucose lowering - 6 months 6 6 0.94 0.92, 0.96 91 88, 94 99.8 99.7, 99.9 98 99 
- 3 months 6 6 0.88 0.85, 0.91 92 88, 95 99.1 98.7, 99.4 86 99 
Thiazide - 6 months 9 10 0.85 0.82, 0.87 82 79, 86 99 98.7, 99.4 90 98 
- 3 months 9 7 0.75 0.72, 0.79 88 85, 92 97 96.6, 97.6 69 99 
Angiotensin - 6 months 46 50 0.88 0.86, 0.89 89 88, 90 98.5 98.0, 99.0 98 90 
- 3 months 46 48 0.87 0.86, 0.88 91 90, 92 96 95.0, 97.0 95 92 
Beta Blockers - 6 months 20 23 0.83 0.81, 0.85 80 77, 82 98.5 98.0, 99.0 94 94 
- 3 months 20 20 0.79 0.76, 0.81 81 79, 84 96 95.5, 96.8 84 95 
Statin - 6 months 32 36 0.90 0.89, 0.91 89 87, 90 99.3 99.0, 99.6 99 94 
- 3 months 32 34 0.90 0.89, 0.91 91 89, 92 98 97.5, 98.5 96 95 
Depression - 6 months 12 16 0.80 0.77, 0.82 72 68, 75 99.6 99.4, 99.8 97 95 
- 3 months 12 14 0.82 0.79, 0.84 78 75, 81 98.9 98.6, 99.3 92 97 
Drugs that may be used  
sporadically and cannot be 
bought over-the-counter: 
          
Insulin - 6 months 0.9 1.2 0.72 0.62 , 0.82 63 50, 75 99.8 99.7, 99.9 85 99 
- 3 months 0.9 0.8 0.60 0.47, 0.73 66 50, 81 99.6 99.4, 99.8 56 99 
Nervous System** - 6 months 10 21 0.44 0.41 , 0.48 37 34, 40 98 97.6, 98.5 83 85 
- 3 months 10 16 0.47 0.44 , 0.51 43 39, 46 96.8 96.3, 97.4 72 90 
Drugs that can be  
bought over-the-counter:           
Folic acid - 6 months 3 3.5 0.60 0.54 , 0.67 60 52, 67 98.8 98.4, 99.1 63 99 
- 3 months 3 2 0.48 0.40 , 0.55 65 55, 75 98 97.6, 98.4 39 99 
Aspirin - 6 months 33 25 0.50 0.47 , 0.52 75 72, 77 80 79.0, 82.0 55 91 
- 3 months 33 15 0.35 0.33 , 0.38 79 76, 82 75 73.0, 76.0 35 95 
*95% CI = 95% confidence interval, **Anxiolytics, hypnotics and sedatives. 
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data [15]. Kappas are generally higher for the six month 
retrieval period than the three month retrieval period, 
with aspirin, folic acid, medicines used for the nervous 
system and insulin having the lowest agreement. 
Sensitivity declines with longer retrieval periods, where- 
as specificity increased with longer retrieval periods. Si- 
milarly, positive predictive values increased with longer 
retrieval periods whereas negative predictive values de- 
creased. Sensitivity was lowest for medicines used for 
the nervous system (including anxiolytics, hypnotics and 
sedatives which may be used on an as needed basis) with 
a sensitivity of only 37% when using a six month re- 
trieval period. 
Women were most likely to accurately report glucose 
lowering medicines, thiazides, angiotensins, betablockers 
and statins (sensitivity > 80%). Specificity was consis- 
tently high across all medicines classes. Positive and ne- 
gative predictive values measure how well a test per- 
forms in a given population with a given prevalence of 
use and are not fixed. Positive predictive values were low- 
est for aspirin, folic acid, and insulin (three months). The 
low positive predictive value of 56% for insulin means 
that amongst those who report insulin use only 56% are 
true positives according to pharmaceutical claims records 
and this may be explained by the low prevalence of insu- 
lin (0.9%). Negative predictive values reached high to 
very high levels. 
4. DISCUSSION 
The purpose of the present study was to estimate the 
agreement and accuracy of self-report survey medicines 
data by comparing it with PBS/RPBS claims data as the 
reference standard. Good to excellent agreement was 
found between self-report compared to the pharmaceuti- 
cal claims dataset for repeat medicines. Aspirin, folic 
acid and medicines used for the nervous system had the 
lowest agreement and women were also least able to ac- 
curately report the use of these medicines. Women were 
most likely to accurately report glucose lowering medi- 
cines, thiazides, angiotensins, betablockers and statins 
(sensitivity > 80%). Specificity was consistently high 
across all medicine classes, suggesting that if women re- 
ported using a medicine this was likely to be valid. 
Prevalence of medicines use was generally higher in 
pharmaceutical claims data except for aspirin intake at 
three and six months and folic acid, insulin and thiazides 
at three months and these medicines generally had low 
positive predictive values for the three month period. 
These effects could be accounted for by over-the-counter 
purchases of aspirin and folic acid which will not appear 
in the pharmaceutical claims data, if women received 
more than three months’ supply of the medicine each 
time it was dispensed, or if women had less than optimal 
compliance and so the prescription lasted longer than 
three months. Likewise medicines used on an as needed 
basis will also not necessarily show high levels of agree- 
ment or predictive values. Sensitivity declined with in- 
creased retrieval periods since women may no longer be 
using medicines prescribed in the more distant past. 
Consenters were better educated and were more likely 
to be able to manage on their available income. However, 
most studies have not demonstrated a relationship be- 
tween education [8,9,21] and income [21] with recall ac- 
curacy. Additionally, the bias will vary per medicine 
class. Haapea et al. [3] showed that more education only 
led to better recall for antidepressants but not for beta- 
blockers, antidiabetics, antiepileptics and antipsychotics. 
Poor health has also been shown to be related to poorer 
self-report of medicines amongst low-income older adults 
[5] but no differences were found in our study between 
consenters and non-consenters in relation to self-rated 
health, diabetes, Body Mass Index, and number of gen- 
eral practitioner visits which suggest that this potential 
bias may not be relevant in our study. Some of the dif- 
ferences in agreement may be explained by medicines 
that are not recorded in the pharmaceutical claims dataset, 
for example when women reach the Safety Net or their 
medicines fall below the co-payment threshold, or re- 
ceive medicines while hospitalised. 
Care should be taken when comparing the results with 
other studies given the variability in methods used such 
as differing recall period, study populations, question 
structure and comparators. The 8% of women who re- 
ported not using any prescription medicines is similar to 
another Australian study using the same methods, recall 
period, database and similar question structure in an 
older population [1,22]. The main difference was that this 
was a sample selected from a general practice population 
and included men and women. Although the medicines 
classes were slightly different, the accuracy for antihyper- 
glycaemics was reasonably similar to the glucose lower- 
ing medicines category used in this study [1]. Both stud- 
ies confirmed that older people report cardiovascular and 
glucose lowering medicines accurately. The prevalence 
for medicines used for the nervous system was similar 
between both studies (10%) but the Kappa was much 
lower in this community study when compared to the ge- 
neral practice study (0.47 versus 0.89) as was sensitivity 
(43% versus 74%). Finally, while the general practice 
population reported a much higher thiazide diurectics use 
(19%) than did the Australian Longitudinal Study on 
Women’s Health sample (9%), both studies showed very 
high agreement and validity for this commonly used 
class of medicines. Caskie [5] noted in an American 
study that agreement between self-report and pharmaceu- 
tical claims data was higher for medicines with a higher 
prevalence. This was in general not the case in the cur- 
rent study. It is possible that given this study has a much 
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larger sample size that low prevalence becomes less of 
an issue and more precise estimates of sensitivity, speci- 
ficity and predictive values can be determined. 
The study had some limitations. The data did not allow 
for analyses of compliance issues. Additionally, the dif- 
ferences between national pharmaceutical claims data- 
bases can make comparison between countries difficult. 
Agreement and accuracy cannot be generalised to other 
medicines classes or other populations but can be useful 
for other researchers working with self-report data. A 
strength of this study was that this is the first study that 
has compared self-reported medicines use with pharma- 
ceutical claims data for a nationally representative sam- 
ple of older women. 
The generalisability of the study findings is confined 
to older women living in the community. Measuring me- 
dicines use through pharmaceutical claims database has 
limitations. Care must be taken when using pharmaceu- 
tical claims data as a source of information about medi- 
cines that can be bought over-the-counter or that are used 
as needed. Medicines that are not covered under the PBS/ 
RPBS scheme will also be under-represented in pharma- 
ceutical claims data and self-report may be a better 
source of information on the use of these medicines. Ap- 
propriate consideration must be given to the pharma- 
ceutical claims data retrieval period to understand the 
accuracy of self-report data [1,12]. It is also important to 
understand the intricacies of the pharmaceutical claims 
data to determine whether pharmaceutical claims data or 
self-report produce more valid results. For example, if a 
researcher knows that a medicine falls under a co-pay- 
ment threshold, it may be better to use self-report rather 
than claims data. 
This study demonstrated that medicines that can be 
bought over-the-counter (aspirin and folic acid) should 
be measured by self-report rather than claims data. Me- 
dicines that may be used sporadically and that can not be 
bought over-the-counter such as benzodiazepines benefit 
less from self-report especially if the recall period in- 
creases. Medicines that are used daily, and can not be 
bought over-the-counter (glucose lowering drugs, thi- 
azides, angiotensins, beta blockers, and statins) can accu- 
rately be self-reported by older women. 
In conclusion, for several medicine classes, high agree- 
ment and accuracy were demonstrated for self-reported 
use of medicines of older women when compared with 
pharmaceutical claims data. Pharmaceutical claims data 
and self-reported medicines use can be useful in the 
evaluation of medicines use. Pharmaceutical claims data 
can also be used to track medicines expenditure, particu- 
larly for chronic conditions requiring repeat prescriptions. 
Studies that require measurement of medicines that can 
be bought over-the-counter or that are not covered by 
pharmaceutical claims data or medicines used on an as 
needed basis would benefit from using self-report meth- 
ods and must take care when using pharmaceutical claims 
data to measure use of these types of medicines. 
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APPENDIX  
Medicines groups, generic names and ATC-codes [15]. 
Medicines category Medicines ATC code 
Diabetic medicines   
Insulin and analogues Insulins (fast-acting, long-acting) A10A 
Blood glucose lowering medicines, excluding insulins 
Metformin 
Sulfonamides 
Glucosidase inhibitors 
Thiazolidinediones, etc. 
A10B 
Anti-hypertensives, statins, aspirin and folic acid   
Thiazide diuretic 
Thiazides, plain  
Hydrochlorothiazide and potassium 
Hydrochlorothiazide, combinations 
Hydrochlorothiazide and potassium-sparing agents 
C03AA 
C03AB03 
C03AX01 
C03EA01 
Angiotensin II receptor antagonists or angiotensin 
converting enzyme inhibitor 
Agents acting on the renin-angiotensin system  
Angiotensin-Converting Enzyme (Ace) inhibitors, plain 
converting enzyme blockers 
C09  
C09AA 
Beta blocker Beta blocking agents, non-selective Beta blocking agents, selective 
C07AA  
C07AB 
Statin Cholesterol- and triglyceride reducers HMG COA reductase inhibitors C10AA 
aspirin 
Acetylsalicylic acid 
Codeine, combinations excl. psycholeptics 
Acetylsalicylic acid 
Acetylsalicylic acid, combinations excl.psycholeptics 
B01AC06  
N02AA59  
N02BA01  
N02BA51 
Folic acid 
 
Ferrous sulfate 
Folic acid and derivatives 
Iron, multivitamins and folic acid 
Iron, vitamin B12 and folic acid 
 
B03AD03  
B03BB  
B03AE02  
B03AE01 
Psychotropic medicines   
Antidepressants Non-selective monoamine reuptake inhibitors N06AA 
 Selective serotonin reuptake inhibitors N06AB 
 Monoamine oxidase inhibitors, non-selective Monoamine oxidase type A inhibitors 
N06AF  
N06AG 
 Other antidepressants N06AX 
Nervous system Anxiolytics N05B 
 Hypnotics and sedatives N05C 
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